Clinical Pilot - Alpha-1 Foundation
Clinical Pilot supports investigators, including those new to Alpha-1 research, in testing hypotheses and methods in human subjects to generate preliminary data for larger studies of AAT deficiency.
Browse similar grants
Funder: Alpha-1 Foundation
Due Dates: September 25, 2026 (LOI) | November 27, 2026 (Invitation notification) | February 12, 2027 (Full application) | April 2027 (Funding decisions)
Funding Amounts: Up to $75,000 for one year (maximum total award: $75,000)
Summary: Supports human-subject research testing new hypotheses and methods relevant to alpha-1 antitrypsin deficiency and generating preliminary data for larger studies.
Key Information: Pharmaceutical companies, biotechs, and industry cannot apply or collaborate on in-cycle proposals.
Description
The Alpha-1 Foundation’s Clinical Pilot grant supports projects involving human subjects that develop and test new hypotheses or methods relevant to alpha-1 antitrypsin (AAT) deficiency, including methods applied to Alpha-1 problems for the first time. It also supports promising new investigators establishing themselves in Alpha-1 research. The grant is part of the Foundation’s 2026–2027 In-Cycle Grants Award Program, which seeks to improve the health of people with AAT deficiency and ultimately find a cure.
Clinical Pilot awards enable investigators to collect preliminary data and identify strategies for major research questions that will ultimately require larger-scale studies or multicenter collaborative trials. Results should lead to applications for funding from other agencies, such as NIH. The program sits within the Foundation’s broader mission to advance rigorous research on Alpha-1-related lung and liver disease, treatment, and care.
